| 0.7001 -0.036 (-4.85%) | 07-08 12:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.09  |
1-year : | 1.23 |
| Resists | First : | 0.93 |
Second : | 1.05 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.73 |
Second : | 0.61 |
| MAs | MA(5) : | 0.8 |
MA(20) : | 0.84 |
| MA(100) : | 0.91 |
MA(250) : | 1.21 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.2 |
D(3) : | 19.5 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 3.3 | Low : | 0.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RDHL ] has closed below the lower bollinger band by 1.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.78 - 0.78 | 0.78 - 0.79 |
| Low: | 0.72 - 0.73 | 0.73 - 0.74 |
| Close: | 0.72 - 0.74 | 0.74 - 0.75 |
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Thu, 02 Jul 2026
RedHill Biopharma (RDHL) registers 26.2M ADSs for selling shareholders - Stock Titan
Wed, 01 Jul 2026
RedHill Biopharma (NASDAQ: RDHL) plans 2026 AGM on CEO role and share par value - Stock Titan
Mon, 29 Jun 2026
RedHill Biopharma (RDHL) raises ADS at-the-market offering limit - Stock Titan
Mon, 29 Jun 2026
RedHill Biopharma (NASDAQ: RDHL) raises ATM capacity to $2.128M - Stock Titan
Sat, 27 Jun 2026
Enterprise value to revenue forward of Redhill Biopharma Ltd. – NASDAQ:RDHL - TradingView
Mon, 22 Jun 2026
RedHill Biopharma (RDHL) prices $6M ADS private placement with warrants - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.05e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.79e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -150 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 765.3 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 286000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 57545.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 4.35 |
| Dividend | 0 |
| Forward Dividend | 14180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|